Abstracts tagged "Outcome measures"

Abstract Number: 0168 • ACR Convergence 2025
Risk of hospitalization in patients with rheumatoid arthritis-associated interstitial lung disease or bronchiectasis: A matched cohort study
QIANRU ZHANG¹, Ying Qi², Xiaosong Wang³, Gregory McDermott⁴, Sung Hae Chang⁵, Liya Sisay Getachew⁶, Mark Chaballa⁷, Vadim Khaychuk⁸, Misti Paudel⁹, Katherine Liao¹⁰ and Jeffrey Sparks⁶, ¹Brigham and Women’s Hospital/Beijing Tsinghua Changgung Hospital, Cambridge, MA, ²Brigham and Women’s Hospital, Boston, ³Brigham and Women's Hospital, Natick, MA, ⁴Brigham and Women's Hospital, Brookline, MA, ⁵Soonchunhyang University College of Medicine, Cheonan, MA, South Korea, ⁶Brigham and Women's Hospital, Boston, MA, ⁷Bristol Myers Squibb, Princeton, NJ, ⁸Bristol Myers Squibb, Pennington, NJ, ⁹Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, ¹⁰Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital, Boston, MA, USA, Boston, MA
Background/Purpose: RA-associated lung disease (RA-LD), including RA-associated interstitial lung disease (RA-ILD) and RA-associated bronchiectasis (RA-BR), is a serious extra-articular manifestation of RA that significantly contributes…
Abstract Number: 2465 • ACR Convergence 2025
CD19/BCMA Dual-Targeting FasTCAR-T Cells GC012F (AZD0120) in patients with refractory Systemic Lupus Erythematosusm: an open-label, single-center Phase I study
chunmei Wu¹, Yakai Fu², Jia Liu³, Yan Ye⁴, Ran Wang⁵, Xintong Feng³, Lianjun Shen⁶, Peiying Li⁵, Shuang Ye⁵ and Qiong Fu⁷, ¹Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China, Shanghai, China (People's Republic), ²Department of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, Shanghai, China (People's Republic), ³Astrazeneca, Shanghai, China (People's Republic), ⁴Department of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China (People's Republic), ⁵Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China, Shanghai, Shanghai, China (People's Republic), ⁶Astrazeneca, Shanghai, Shanghai, China (People's Republic), ⁷Renji Hospital, Shanghai, Shanghai, China
Background/Purpose: GC012F (AZD0120) is a CD19/B cell maturation antigen (BCMA) dual-targeting chimeric antigen receptor T-cell (CAR-T) developed on the novel FasTCAR-T platform with next-day manufacturing,…
Abstract Number: 2307 • ACR Convergence 2025
Peripheral Manifestations In Axial And Peripheral Spondyloarthritis: A Systematic Literature Review On Their Assessment In Clinical Trials
AUGUSTA ORTOLAN¹, Casper Webers², Elena Nikiphorou³, Alexandre Sepriano⁴, Louise Falzon⁵, Clementina López Medina⁶, Dafne capelusnik⁷, Désirée Van Der Heijde⁸, Anna Molto⁹ and Sofia Ramiro¹⁰, ¹Policlinico Universitario Agostino Gemelli IRCSS, Rome, Italy, ²Maastricht University Medical Centre, Maastricht, Netherlands, ³King's College London, London, United Kingdom, ⁴Department of Rheumatology, Leiden University Medical Centre, Portela Loures, Portugal, ⁵Sheffield Centre for Health and Related Research, University of Sheffield, Sheffield, United Kingdom, ⁶Department of Medicine, Hospital Universitario Reina Sofia, University of Cordoba, IMIBIC, Cordoba, Spain, ⁷Tel Aviv Sourasky Medical Center, Ramat Gan, Israel, ⁸Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁹Assistance Publique Hôpitauxde Paris, Paris, France, ¹⁰Leiden University Medical Center, Bunde, Netherlands
Background/Purpose: Peripheral manifestations (peripheral arthritis, enthesitis, dactylitis) of axial spondyloarthritis (axSpA) and peripheral spondyloarthritis (pSpA) represent a significant burden for patients, but are understudied. Our…
Abstract Number: 2032 • ACR Convergence 2025
Validation of systemic Juvenile Arthritis Disease Activity Score 10 (sJADAS 10) in adult patients with Still’s Disease
Georgia-Savina Moysidou¹, Spyridon Katechis², Stéphane Mitrovic³ and Bruno Fautrel⁴, ¹Sorbonne université, Service de rhumatologie, groupe hospitalier Pitié-Salpêtrière, Assistance publique-Hôpitaux de Paris, Athens, Greece, ²National and Kapodistrian University of Athens Medical School, Athens, Greece, Athens, Greece, ³Sorbonne université, Service de rhumatologie, groupe hospitalier Pitié-Salpêtrière, Assistance publique-Hôpitaux de Paris, Paris, France, ⁴Sorbonne Université - APHP, Department of Rheumatology, Hôpital Pitié-Salpêtrière, Inserm UMRS ¹¹³⁶-⁵, PARIS, France, Paris, France

Background/Purpose: Recent EULAR/PReS recommendations have acknowledged the lack of unique and consensual tool to quantify disease activity in Still’s disease (SD). The systemic Juvenile Arthritis…
Abstract Number: 1555 • ACR Convergence 2025
Prevalence of Organ Involvement and Baseline Predictors of Disease Progression in Patients with Limited Cutaneous Systemic Sclerosis: Insights from the CONQUER Database
Alain Lescoat¹, Virginia Steen², Monica Harding³, John VanBuren³, Brian Skaug⁴, Shervin Assassi⁵, Maureen Mayes⁶, Zsuzsanna McMahan⁷, Elana Bernstein⁸, Flavia Castelino⁹, Lorinda Chung¹⁰, Luke Evnin¹¹, Tracy Frech¹², Jessica Gordon¹³, Faye Hant¹⁴, Laura Hummers¹⁵, Kimberly Lakin¹³, Dorota Lebiedz-Odrobina³, Yiming Luo¹⁶, Ashima Makol¹⁷, Jerry Molitor¹⁸, Duncan Moore¹⁹, Carrie Richardson¹⁹, Nora Sandorfi²⁰, Ami Shah¹⁵, Ankoor Shah²¹, Elizabeth Volkmann²², Carleigh Zahn²³ and Dinesh Khanna²⁴, ¹CHU Rennes - University Rennes, Rennes, France, ²Georgetown University School of Medicine, Washington, DC, ³University of Utah, Salt Lake City, UT, ⁴UTHealth Houston Division of Rheumatology, Houston, TX, ⁵Division of Rheumatology, UTHealth Houston, Houston, Texas, USA, Houston, TX, ⁶UT Health Houston Division of Rheumatology, Houston, TX, ⁷UT Health Houston, Houston, TX, ⁸Columbia University Irving Medical Center, New York, NY, ⁹Massachusetts General Hospital, Boston, MA, ¹⁰Stanford University, Stanford, CA, ¹¹Scleroderma Research Foundation, San Francisco, CA, ¹²Vanderbilt University Medical Center, Nashville, TN, ¹³Hospital for Special Surgery, New York, NY, ¹⁴Medical University of South Carolina, Charleston, SC, ¹⁵Johns Hopkins Rheumatology, Baltimore, MD, ¹⁶Columbia University Irving Medical Center, New York, ¹⁷Mayo Clinic, Rochester, MN, ¹⁸University of Minnesota, Minneapolis, MN, ¹⁹Northwestern University, Chicago, ²⁰University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, ²¹Duke University, Durham, NC, ²²Division of Rheumatology, Department of Medicine, University of California, David Geffen School of Medicine, Los Angeles, CA, USA, Los Angeles, CA, ²³University of Michigan, Ann Arbor, ²⁴University of Michigan, Ann Arbor, MI
Background/Purpose: Systemic sclerosis (SSc) is characterized by a wide range of clinical manifestations and available interventions still lack overall efficacy. Limited cutaneous SSc (lcSSc) and…
Abstract Number: 1300 • ACR Convergence 2025
International Assessment of cSLE Clinical Remission (cCR) Criteria in Childhood Lupus: Sensitivity Analyses from the UK JSLE Cohort and the CARRA Registry
Chandni Sarker¹, Jennifer Cooper², Emily Smitherman³, Flavia Alves¹, Alexandre Belot⁴, Michael Beresford⁵, Andreea Jorgensen¹, Eve Smith⁶, Laura Lewandowski⁷ and Rebecca Sadun⁸, ¹University of Liverpool, Liverpool, United Kingdom, ²University of Colorado/Children's Hospital Colorado, Aurora, CO, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Hospices Civils de Lyon, Collonges au mont d'or, France, ⁵Alder Hey Children's NHS Foundation Trust Hospital, Department of Women's & Children's Health, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, United Kingdom, ⁶University of Glasgow, Glasgow, United Kingdom, ⁷NIAMS, NIH, Bethesda, MD, ⁸Duke University, Durham, NC
Background/Purpose: Consensus-derived treat-to-target (T2T) goals for childhood-onset SLE (cSLE), including clinical remission on low dose steroids (cCR), have been endorsed by the Paediatric Rheumatology European…
Abstract Number: 1035 • ACR Convergence 2025
Demographic and Clinical Correlates of 30 day Re-admission or Death During Admission in Patients With Rheumatologic Conditions : A Retrospective Cohort Analysis in a Single Academic Center
Waleed Ali¹ and Deepali Sen², ¹Wash U/BJH, St. Louis, MO, ²Washington University in St Louis, Chesterfield, MO
Background/Purpose: Rheumatology consults are often obtained in hospitalized patients with known or suspected rheumatologic disease. Identifying factors linked to poor short-term outcomes may improve risk…
Abstract Number: 0769 • ACR Convergence 2025
Increased Gait Variability at Preferred Walking Speeds is Associated with Increased Physical Activity Measures in People with Knee Osteoarthritis
Ogundoyin Ogundiran, Steven Garcia, Joy Itodo, Oiza Peters and Kharma Foucher, UNIVERSITY OF ILLINOIS, CHICAGO, Chicago, IL
Background/Purpose: People with knee osteoarthritis (OA) often exhibit reduced physical activity levels and increased fall risk. Gait variability, specifically center of mass (COM) variability is…
Abstract Number: 0385 • ACR Convergence 2025
Musculoskeletal Ultrasound Enhances Patient Insight and Clinical Decisions: A Multi-Center Study
Simran Nimal¹, Meridith Balbach², Aslam Fawad¹, Midori Nishio³ and Erin Chew², ¹Mayo Clinic Arizona, Scottsdale, AZ, ²Vanderbilt University, Nashville, TN, ³John Muir Specialty Medical Group, Lafayette, CA
Background/Purpose: Musculoskeletal ultrasound (MSKUS) is a valuable tool for early detection and management of inflammatory arthritis.(1) Although integrated into rheumatology guidelines, training programs, and classification…
Abstract Number: 0149 • ACR Convergence 2025
Effect Of Osteoporosis And Opioid Use On Mortality And Unplanned Healthcare Utilization Among Patients With Rheumatoid Arthritis
Viengneesee Thao, Molly Moore Jeffery, Nafisseh Warner and Elena myasoedova, Mayo Clinic, Rochester, MN
Background/Purpose: Patients with rheumatoid arthritis (RA) have a 2-fold increase in risk for osteoporosis compared to the general population. About 30-50% of RA patients experience…
Abstract Number: 2420 • ACR Convergence 2025
In-patient Outcomes of Diabetic Ketoacidosis and Hyperglycemic Hyperosmolar Syndrome in SLE: US National Inpatient Database (2021-2022)
Nattanicha Chaisrimaneepan¹, Pitchaporn Yingchoncharoen² and Miriam Paz², ¹Department of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, ²Texas Tech University Health Sciences Center, Lubbock
Background/Purpose: Systemic lupus erythematosus (SLE is an autoimmune disease that attacks different organs. There have been reports of hyperglycemic hyperosmolar syndrome (HHS) from steroid use…
Abstract Number: 2302 • ACR Convergence 2025
Clustering by ESSPRI and PROMIS domain measures defines distinct subtypes and facilitates longitudinal assessment of patients with Sjogren’s disease
Thomas Grader-Beck¹, Jennifer Reed², Priya Patel³, Ji Soo Kim⁴ and Alan Baer⁵, ¹Johns Hopkins, Reisterstown, MD, ²Johns Hopkins, Freeland, MD, ³Johns Hopkins, Annville, PA, ⁴Johns Hopkins, Baltimore, MD, ⁵Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Patient-reported outcomes (PROs) measure a patient’s health-related quality of life. The role of ESSPRI and PROMIS measures in identifying subsets of patients with Sjogren’s…
Abstract Number: 2003 • ACR Convergence 2025
Evaluating Patient Outcomes Pre and Post Pegloticase Initiation among Uncontrolled Gout Patients: Findings from MORE2 Registry and Medicare Fee-For-Service Claims Data
Julia Buchfuhrer¹, Niranjan Kathe², Elizabeth Ibiloye³, Seth Kuranz⁴, Virginia Noxon-Wood⁴, Alexis Woods⁵ and Laurence Gozalo⁴, ¹JB Arthritis and Rheumatology Center, Downey, CA, ²Amgen Inc, San Diego, CA, ³Amgen Inc, Thousand Oaks, CA, ⁴Inovalon, Bowie, MD, ⁵Amgen, Detroit, MI
Background/Purpose: Among patients (pts) with chronic refractory gout (CRG), traditional urate lowering therapies are often inadequate, necessitating advanced therapies. Pegloticase, a recombinant uricase enzyme, rapidly…
Abstract Number: 1531 • ACR Convergence 2025
Achieving Remission and Low Disease Activity with Belimumab Versus Placebo in Patients with SLE Excluding the Glucocorticoid Component from Target Definitions: A Post Hoc Analysis of Five Phase 3 Trials
Ioannis Parodis¹, Julius Lindblom², Roger A. Levy³, Alexander Tsoi¹, Margherita Zen⁴, Dionysis Nikolopoulos⁵, Munther Khamashta⁶, Ryan Tomlinson⁷, Anca Askanase⁸, Ronald van Vollenhoven⁹ and Mandana Nikpour¹⁰, ¹Karolinska Institutet and Karolinska University Hospital, Department of Medicine Solna, Division of Rheumatology, Stockholm, Sweden, ²Karolinska Institutet, Stockholm, Sweden, ³GSK, Specialty Care, Global Medical Affairs, Collegeville, PA, ⁴University of Padua, Department of Medicine, Division of Rheumatology, Padua, Italy, ⁵Karolinska Institutet and Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden, ⁶GSK, Medical Affairs, Dubai, United Arab Emirates, ⁷GSK, Development – R&D, Collegeville, PA, ⁸Columbia University Medical Center, New York, NY, ⁹Amsterdam Rheumatology and Immunology Center, Amsterdam University Medical Centers, Department of Rheumatology, Amsterdam, Netherlands, ¹⁰University of Sydney School of Public Health and Department of Rheumatology, Royal Prince Alfred Hospital, Sydney, Victoria, Australia
Background/Purpose: An integrated post hoc analysis of five Phase 3 trials in adults with SLE showed greater benefit of belimumab (BEL) than placebo (PBO), plus…
Abstract Number: 1291 • ACR Convergence 2025
Gastrointestinal Tract Involvement in Juvenile Systemic Sclerosis: Results from an International Scoping Review of Outcome Measures
Lauren Robinson¹, Lusine Ambartsumyan², Emily Willis³, Aybuke Gunalp⁴, Simone Appenzeller⁵, Ozgur Kasapcopur⁶, Sarah Ishaq⁷, Natalia Vasquez Canizares⁸ and Suzanne Li⁹, ¹Hospital for Special Surgery, New York, NY, ²Seattle Children's Hospital, Seattle, WA, ³Royal Manchester Children's Hospital, Manchester, United Kingdom, ⁴Cerrahpasa Medicine School, Cerrahpasa, Istanbul, Turkey, ⁵Unicamp, Campinas, São Paulo, Brazil, ⁶Istanbul University-Cerrahpasa, Cerrahpasa Medical School, istanbul, Turkey, ⁷Osteopathic Medicine , Touro College of Osteopathic Medicine, New York, NY, ⁸Children's Hospital at Montefiore, New York, NY, ⁹Joseph M. Sanzari Children's Hospital and Hackensack Meridian School of Medicine, Hackensack, NJ

Background/Purpose: Gastrointestinal (GI) tract involvement is nearly universal in patients with systemic sclerosis (SSc) leading to significant morbidity and mortality. In a North American juvenile…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].